Healthcare

An internal audit at PACS Group delayed financial reports for three consecutive quarters in 2024 as well as for the first quarter of 2025.

Abbott Laboratories agrees to buy the cancer screening company for $105 a share in a cash deal.

Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.

A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.

The latest market sell-off is another sign of tech/AI froth. But there are other pockets of the market that still look attractive.

Recent market turmoil led by an artificial-intelligence selloff seems like the perfect opportunity for lagging, less risky areas of the market to shine. Not all seem up to the task. 

Medtronic exceeds fiscal second-quarter earnings and revenue expectations.

Alphabet rose after Berkshire Hathaway disclosed that it bought $4.3 billion worth of shares in the third quarter.

The increase will soak up much of an increase in Social Security payments to account for inflation.

The companies’ drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.

Companies are building workplaces with clean air, restaurants, even farmers markets to entice reluctant employees.

It may seem crazy to move money out of shares, considering how well equities have done.

The sector is up almost 7% since the start of November, while the broader market is down more than 1%.

Fallout from the government shutdown, Chevron expands electricity business, Cisco beats expectations, and more news to start your day.

The membership clubs charge annual fees for access to doctors, extra testing, and perks like an Oura ring. Are they worth the cost?

BigBear.ai surges after striking a deal to acquire a generative AI platform, while Nebius falls after missing analysts’ estimates.

Warren Buffett posts final Thanksgiving letter as Berkshire CEO, CoreWeave beats earnings expectations, hopes fade for extended ACA subsidies, and more news to start your day.

The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.

The bullish note comes after the company reached a landmark deal with the U.S. government.

Flight delays and government-data blackouts are set to continue as Congress moves toward reopening the government.

Insurance and hospital stocks were the worst performers in the S&P 500 on Monday.

The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.

It’s been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.

Artificial intelligence is better than Google or WebMD and could help your doctor be more efficient, but don’t skip an office visit.